Rocket Pharma's RP-A601: Gene Therapy Targeting Sudden Cardiac Death from PKP2-ACM

31 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Greetings, fellow investors! Welcome back to ShareTreck. I'm Raj, .In this video, I break down Rocket Pharmaceuticals' gene therapy RP-A601, which targets a rare inherited heart disease called PKP2-related arrhythmogenic cardiomyopathy. This therapy uses AAVrh74 to deliver a healthy PKP2 gene and early results show improved heart function and reduced arrhythmia risk. We also explore what this means for gene therapy investors.

Your feedback is invited.

Well this is my personal opinion, not financial advice.

JOIN THE CHANNEL AS A MEMBER:

Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter. Join the channel and share your ideas.

https://www.youtube.com/channel/UCLfA-8l-TE2n-VH-WBKycEg/join

Please subscribe: https://www.youtube.com/channel/UCLfA-8l-TE2n-VH-WBKycEg?sub_confirmation=1

The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
In case of coverage of pharma companies, disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.
Categoria
Cardiology
Commenta per primo questo video.

Prossimo